Glycemic Outcomes Beyond A1C: Standardization and Implementation
Welcome and Review Objectives of Consensus Conference – Kelly Close & Dr. Janet Woodcock (8:00 – 8:15 am)
SESSION I – Limitations of A1C, Evolving Technology, and Beyond (8:15 – 9:55 am)
- Limitations of A1C – Dr. Robert Ratner (8:15 – 8:35 am)
- Presentation of data on the importance of outcomes beyond A1C – Richard Wood (8:35 – 8:55 am)
- Evolving Technology: Update on Tools – Dr. Bruce Buckingham (8:55 – 9:15 am)
- Implications of New Technology and Tools for Clinical Trials – Prof. Philip Home (9:15 – 9:35 am)
- Glycemic Outcomes Beyond A1C: The European Perspective – Prof. Bart Van der Schueren (9:35 – 9:55 am)
Break (9:55 – 10:15 am)
SESSION II – Standardization of Data, Definitions, and Terminology (10:15 -11:55 am)
- Definitions Regarding Euglycemia, Hypoglycemia, Hyperglycemia, and Glycemic Variability - Setting the Stage: Why is this a Critical Conversation? – Dr. Rich Bergenstal (10:15 – 10:35 am)
- PANEL discussion – moderated by Dr. Rich Bergenstal & Adam Brown: (10:35 – 11:55 am)
- Dr. Aaron Kowalski (JDRF)
- Dr. Will Cefalu (ADA)
- Prof. Thomas Danne (ATTD)
- Prof. Stephanie Amiel (IHSG)
- Dr. Zach Bloomgarden (AACE)
- Dr. Anthony McCall (Endocrine Society)
SESSION III – WORKING LUNCH: Issues of Importance to Patients and Providers – Moderated by David Lee Strasberg (11:55 am – 1:00 pm)
- Update from the Community: The diaTribe Foundation and DSMA shares data regarding patient experience – Kelly Close, Adam Brown, & Cherise Shockley (11:55 am – 12:40 pm)
- Perspectives on Terminology – Dr. Jane K. Dickinson (12:40 – 1:00 pm)
SESSION IV – Public Open Session (1:00 – 2:15 pm)
SESSION V – Working Sessions: Facilitated discussion in small groups (2:15 – 3:45 pm)
Goal: Discuss key issues and hear views from communities (scientific, research, clinical)
Break into small groups to discuss “Glycemic Outcomes Beyond A1C” topics and share opinions Each group will have the opportunity to discuss topics related to glycemic outcomes beyond A1C in a smaller setting and report back.
- Glucose metrics including glycemic variability (General Session Room) – Drs. Roy Beck & Rich Bergenstal
- Hypoglycemia (Brookside A) – Profs. Stephanie Amiel & Brian Frier
- Future clinical trials and other research questions (Brookside B) – Prof. Philip Home & Dr. Lori Laffel
- Implementation (Linden Oak) – Drs. Jane K. Dickinson & Robert Gabbay
SESSION VI – What We’ve Learned (3:45 – 5:00 pm)
- Report Back of Small Group Discussions – Dr. Charlie Alexander and session representatives (3:45 to 4:30 pm)
- Concluding Thoughts and Next Steps –Dr. Rich Bergenstal and additional leaders (4:30 – 4:55 pm)
- Closing – Kelly Close (4:55 – 5:00 pm)